Oncoprotein MDM2 overexpression is associated with poor prognosis in distinct non-Hodgkin's lymphoma entities

Modern Pathology

Volumn 12, Issue 11, 1999, Pages 1010-1016

  Møller, Michael B ^a,b   Nielsen, Ole ^a   Pedersen, Niels T ^a  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

Immunohistochemistry; Lymphomagenesis; MDM2; Non Hodgkin's lymphoma; P53; Population based; Prognosis

Indexed keywords

ONCOPROTEIN; PROTEIN MDM2; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CARCINOGENESIS; FEMALE; GENE FREQUENCY; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; MANTLE CELL LYMPHOMA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL TIME;

FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOMA, FOLLICULAR; LYMPHOMA, MANTLE-CELL; LYMPHOMA, MUCOSA-ASSOCIATED LYMPHOID TISSUE; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NUCLEAR PROTEINS; PROGNOSIS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2;

EID: 0032710435     PISSN: 08933952     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Oliner JD, Kinzler KW, Meltzer PS, George DL, Vogelstein B. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 1992;358:80-3.
2. Momand J, Zambetti GP, Olson DC, George D, Levine AJ. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992;69:1237-45.
3. Thut CJ, Goodrich JA, Tjian R. Repression of p53-mediated transcription by mdm2: a dual mechanism. Genes Dev 1997; 11:1974-86.
4. Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53. Nature 1997;387:296-9.
5. ARF links the tumour suppressors RB and p53. Nature 1998;395:124-5.
6. Zhang Y, Xiong Y, Yarbrough WG. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 1998;92:725-34.
7. Morgenbesser SD, Williams BO, Jacks T, DePinho RA. p53-dependent apoptosis produced by Rb-deficiency in the developing mouse lens. Nature 1994;371:72-4.
8. Williams BO, Remington L, Albert DM, Mukai S, Bronson RT, Jacks T. Cooperative tumorigenic effects of germline mutations in Rb and p53. Nat Genet 1994;7:480-4.
9. Jones SN, Roe AE, Donehower LA, Bradley A. Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature 1995;378:206-8.
10. Montes de Oca Luna R, Wagner DS, Lozano G. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature 1995;378:203-6.
11. Lundgren K, Luna RMDO, McNeill YB, Emerick EP, Spencer B, Barfield CR, et al. Targeted expression of MDM2 uncouples S phase from mitosis and inhibits mammary gland development independent of p53. Genes Dev 1997;11:714-25.
12. Jones SN, Hancock AR, Vogel H, Donehower LA, Bradley A. Overexpression of Mdm2 in mice reveals a p53-independent role for Mdm2 in tumorigenesis. Proc Natl Acad Sci U S A 1998;95:15608-12.
13. Bueso-Ramos CE, Yang Y, deLeon E, McCown P, Stass SA, Albitar M. The human MDM-2 oncogene is overexpressed in leukemias. Blood 1993;82:2617-23.
14. Watanabe T, Hotta T, Ichikawa A, Kinoshita T, Nagai H, Uchida T, et al. The MDM2 oncogene overexpression in chronic lymphocytic leukemia and low-grade lymphoma of B-cell origin. Blood 1994;84:3158-65.
15. Maestro R, Gloghini A, Doglioni C, Gasparotto D, Vukosavljevic T, De Re V, et al. MDM2 overexpression does not account for stabilization of wild-type p53 protein in non-Hodgkin's lymphomas. Blood 1995;85:3239-46.
16. Cesarman E, Liu YF, Knowles DM. The MDM2 oncogene is rarely amplified in human lymphoid tumors and does not correlate with p53 gene expression. Int J Cancer 1994;56: 457-8.
17. Kawamata N, Miller C, Levy V, Shintaku IP, Koeffler HP, Said JW. mdm-2 oncogene expression in non-Hodgkin's lymphomas. Diagn Mol Pathol 1996;5:33-8.
18. Møller MB, Ino Y, Gerdes A-M, Skjødt K, Louis DN, Pedersen NT. Aberrations of the p53 pathway components p53, MDM2, and CDKN2A appear independent in diffuse large B-cell lymphoma. Leukemia 1999;13:453-9.
19. Reifenberger G, Liu L, Ichimura K, Schmidt EE, Collins VP. Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations. Cancer Res 1993;53:2736-9.
20. Barak Y, Juven T, Haffner R, Oren M. mdm2 expression is induced by wild type p53 activity. EMBO J 1993;12:461-8.
21. Landers JE, Haines DS, Strauss JFI, George DL. Enhanced translation: a novel mechanism of mdm2 oncogene overexpression identified in human tumor cells. Oncogene 1994;9: 2745-50.
22. Capoulade C, Bressac-de Paillerets B, Lefrere I, Ronsin M, Feunteun J, Tursz T, et al. Overexpression of MDM2, due to enhanced translation, results in inactivation of wild-type p53 in Burkitt's lymphoma cells. Oncogene 1998;16:1603-10.
23. Jiang M, Shao ZM, Wu J, Lu JS, Yu LM, Yuan JD, et al. p21/waf1/cip1 and mdm-2 expression in breast carcinoma patients as related to prognosis. Int J Cancer 1997;74:529-34.
24. Cordon-Cardo C, Latres E, Drobnjak M, Oliva MR, Pollack D, Woodruff JM, et al. Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas. Cancer Res 1994;54: 794-9.
25. Würl P, Meye A, Schmidt H, Lautenschläger C, Kalthoff H, Rath FW, et al. High prognostic significance of mdm2/p53 co-overexpression in soft tissue sarcomas of the extremities. Oncogene 1998;16:1183-5.
26. Marks DI, Kurz BW, Link MP, Ng E, Shuster JJ. Lauer SJ, et al. Altered expression of p53 and mdm-2 proteins at diagnosis is associated with early treatment failure in childhood acute lymphoblastic leukemia. J Clin Oncol 1997;15:1158-62.
27. Sanchez E, Chacon I, Plaza MM, Munoz E, Cruz MA, Martinez B, et al. Clinical outcome in diffuse large B-cell lymphoma is dependent on the relationship between different cell-cycle regulator proteins. J Clin Oncol 1998;16:1931-9.
28. Møller MB, d'Amore F, Christensen BE. Testicular lymphoma: a population-based study of incidence, clinicopathological correlations and prognosis. Eur J Cancer 1994;30A:1760-4.
29. Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994;84:1361-92.
30. Hiddemann W, Longo DL, Coiffier B, Fisher RI, Cabanillas F, Cavalli F, et al. Lymphoma classification-the gap between biology and clinical management is closing. Blood 1996;88: 4085-9.